3 completed. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 1 | Completed 1 |
Follow Refractory Lymphoplasmacytic Lymphoma: new trials by email Literature Review of Refractory Lymphoplasmacytic Lymphoma trials Research Report on Refractory Lymphoplasmacytic Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Lenalidomide, Obinutuzumab, Oral Azacitidine - Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Joseph Tuscano | 8 | 2020-10-23 | 2025-04-24 |
| Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Laboratory Biomarker Analysis, Lenalidomide, Nivolumab - Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma | Phase 1 / Phase 2 | Completed | David Bond, MD | 36 | 2017-02-14 | 2026-09-23 |
| Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Pembrolizumab - B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Grade 1 Follicular Lymphoma | Phase 1 | Completed | Kami Maddocks | 2 | 2017-01-12 | 2019-07-30 |
Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Follicular (3) · Lymphoma, Mantle-Cell (3) · Burkitt Lymphoma (2) · Lymphoma, B-Cell (2) · Lymphoma, Large B-Cell, Diffuse (2) · Waldenstrom Macroglobulinemia (2) · Leukemia, Hairy Cell (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1)
Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoma (3) · Lymphoma, Non-Hodgkin (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Blood Protein Disorders (2) · Cardiovascular Diseases (2) · DNA Virus Infections (2) · Epstein-Barr Virus Infections (2) · Hemorrhagic Disorders (2)
Lenalidomide (2) · Azacitidine (1) · Nivolumab (1) · cc-486 (1) · ibrutinib (1) · obinutuzumab (1) · pembrolizumab (1)
David Bond, MD (1) · Joseph Tuscano (1) · Kami Maddocks (1)
United States (3)
David Bond, MD (1) · Joseph M Tuscano (1) · Kami Maddocks, MD (1)
P30CA016058 (1), P30CA093373 (1)